Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 140 participants.

Also called NCT02970669

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose other
Phase
Phase 4
Enrolled
  • 140 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02970669
Other papers using this trial's data
  • The AWAKE-HF Study: Sacubitril/Valsartan Impact on Daily Physical Activity and Sleep in Heart Failure American journal of cardiovascular drugs : drugs, devices, and other interventions, 2021-03 DOI, PubMed 32978755

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02970669. Randomized; double masking; primary purpose other. Start 2016-12-16 (actual); primary completion 2018-03-19 (actual). Results posted on 2019-04-08.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Acronym
AWAKE-HF
Condition
Heart Failure, Reduced Ejection Fraction
Intervention (Drug)
sacubitril/valsartan (LCZ696)
Intervention (Drug)
enalapril
Intervention (Drug)
matching placebo sacubitril/valsartan (LCZ696)
Intervention (Drug)
matching placebo enalapril
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct02970669
Content hash
2b71eba5f84fcb4ab2afc85def1541b2f0294eb6f9533f63f2fd1760141500e3